Preclinical studies using GC-bearing mouse models have shown that intratumorally injection of engineered herpesvirus or adenovirus can induce local tumor regression and enhance CD8+ T cell infiltration, particularly when combined with immune checkpoint blockade or radiation therapy. This evidence concerns the gene CD8A and neoplasm.